Lantern Pharma Inc
LTRN5.310USD
+0.540+11.32%
取引時間 （ET）15分遅れの株価
57.27M時価総額
損失額直近12ヶ月PER
詳細情報 Lantern Pharma Inc 企業名
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
企業情報
企業コードLTRN
会社名Lantern Pharma Inc
上場日Jun 11, 2020
最高経営責任者「CEO」Mr. Panna L. Sharma
従業員数24
証券種類Ordinary Share
決算期末Jun 11
本社所在地1920 Mckinney Avenue
都市DALLAS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号75201
電話番号19722771136
ウェブサイトhttps://www.lanternpharma.com/
企業コードLTRN
上場日Jun 11, 2020
最高経営責任者「CEO」Mr. Panna L. Sharma
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Thu, Jul 17
更新時刻: Thu, Jul 17
株主統計
種類
株主統計
株主統計
比率
Bios Equity Partners, LP.
9.98%
Biological Mimetics, Inc
7.83%
Prophase Labs Inc
5.85%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Other
71.12%
株主統計
株主統計
比率
Bios Equity Partners, LP.
9.98%
Biological Mimetics, Inc
7.83%
Prophase Labs Inc
5.85%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Other
71.12%
種類
株主統計
比率
Corporation
13.68%
Venture Capital
9.98%
Investment Advisor
7.67%
Investment Advisor/Hedge Fund
2.11%
Hedge Fund
1.29%
Individual Investor
0.42%
Research Firm
0.07%
Other
64.78%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
71
3.80M
35.21%
-556.52K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
2023Q1
73
4.92M
45.34%
-1.23M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Bios Equity Partners, LP.
1.08M
9.98%
-157.85K
-12.79%
Jun 13, 2025
Biological Mimetics, Inc
844.13K
7.83%
-70.00K
-7.66%
Apr 15, 2025
Prophase Labs Inc
631.20K
5.85%
--
--
Apr 15, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Mar 31, 2025
CM Management, LLC
200.00K
1.85%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
90.50K
0.84%
+3.53K
+4.06%
Mar 31, 2025
Renaissance Technologies LLC
88.80K
0.82%
+1.50K
+1.72%
Mar 31, 2025
GWM Advisors LLC
59.92K
0.56%
-8.44K
-12.34%
Mar 31, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Mar 31, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
+3.83K
+9.14%
Apr 15, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
